Triple-negative tumors (those that lack estrogen receptors, progesterone receptors, and ERBB2 molecular markers) constitute 15% of BC cases and are generally treated with chemotherapy [8,9], although neither hormone therapies nor specific targets are available for triple-negative tumors. Here, ERBB2 is linked to breast cancer.